I agree that this site is using cookies. You can find further informations here.
X
Kasamon, Yvette L.
83  results:
Search for persons X
?
1

FDA approval summary: Crizotinib for pediatric and young ad..:

Merino, Margret ; Kasamon, Yvette ; Li, Hongshan...
Pediatric Blood & Cancer.  69 (2022)  8 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
2

FDA Approval Summary: Selinexor for Relapsed or Refractory ..:

Kasamon, Yvette L. ; Price, Lauren S.L. ; Okusanya, Olanrewaju O....
The Oncologist.  26 (2021)  10 - p. 879-886 , 2021
Link: https://doi.org/10.1002/..
 
?
3

FDA Approval Summary: Brentuximab Vedotin in First-Line Tre..:

Richardson, Nicholas C. ; Kasamon, Yvette L. ; Chen, Haiyan...
The Oncologist.  24 (2019)  5 - p. e180-e187 , 2019
Link: https://doi.org/10.1634/..
 
?
4

Haploidentical Bone Marrow Transplantation with Post-Transp..:

Elmariah, Hany ; Kasamon, Yvette L. ; Zahurak, Marianna...
Biology of Blood and Marrow Transplantation.  24 (2018)  5 - p. 1099-1102 , 2018
Link: https://doi.org/10.1016/..
 
?
5

Grade II Acute Graft-versus-Host Disease and Higher Nucleat..:

McCurdy, Shannon R. ; Kanakry, Christopher G. ; Tsai, Hua-Ling...
Biology of Blood and Marrow Transplantation.  24 (2018)  2 - p. 343-352 , 2018
Link: https://doi.org/10.1016/..
 
?
6

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-H..:

Kasamon, Yvette L. ; Fuchs, Ephraim J. ; Zahurak, Marianna...
Biology of Blood and Marrow Transplantation.  24 (2018)  5 - p. 1022-1028 , 2018
Link: https://doi.org/10.1016/..
 
?
7

FDA Approval Summary: Midostaurin for the Treatment of Adva..:

Kasamon, Yvette L. ; Ko, Chia-Wen ; Subramaniam, Sriram...
The Oncologist.  23 (2018)  12 - p. 1511-1519 , 2018
Link: https://doi.org/10.1634/..
 
?
8

Prospective study of nonmyeloablative, HLA-mismatched unrel..:

Kasamon, Yvette L. ; Ambinder, Richard F. ; Fuchs, Ephraim J....
Blood Advances.  1 (2017)  4 - p. 288-292 , 2017
Link: https://doi.org/10.1182/..
 
?
9

Post-Transplantation Cyclophosphamide after Bone Marrow Tra..:

Majzner, Robbie G. ; Mogri, Huzefa ; Varadhan, Ravi...
Biology of Blood and Marrow Transplantation.  23 (2017)  4 - p. 612-617 , 2017
Link: https://doi.org/10.1016/..
 
?
10

FDA Approval Summary: Nivolumab for the Treatment of Relaps..:

Kasamon, Yvette L. ; de Claro, R. Angelo ; Wang, Yaping...
The Oncologist.  22 (2017)  5 - p. 585-591 , 2017
Link: https://doi.org/10.1634/..
 
?
11

Nonmyeloablative Haploidentical Bone Marrow Transplantation..:

Klein, Orly R. ; Buddenbaum, Jessica ; Tucker, Noah...
Biology of Blood and Marrow Transplantation.  23 (2017)  2 - p. 325-332 , 2017
Link: https://doi.org/10.1016/..
 
?
12

The Use of Post-Transplantation Cyclophosphamide after Myel..:

Kanakry, Christopher G. ; Bolaños-Meade, Javier ; Kasamon, Yvette L....
Biology of Blood and Marrow Transplantation.  22 (2016)  3 - p. S46-S47 , 2016
Link: https://doi.org/10.1016/..
 
?
13

Risk Factors for Graft-Versus-Host Disease after HLA-Haploi..:

McCurdy, Shannon ; Kanakry, Christopher ; Kasamon, Yvette...
Clinical Lymphoma Myeloma and Leukemia.  16 (2016)  - p. S125-S126 , 2016
Link: https://doi.org/10.1016/..
 
?
14

Initial Experience with Tositumomab and I-131-Labeled Tosit..:

Jacene, Heather ; Crandall, John ; Kasamon, Yvette L....
Molecular Imaging and Biology.  19 (2016)  3 - p. 429-436 , 2016
Link: https://doi.org/10.1007/..
 
?
15

Nonmyeloablative Haploidentical BMT with Post-Transplant Cy..:

Klein, Orly R. ; Buddenbaum, Jessica ; Tucker, Noah...
Biology of Blood and Marrow Transplantation.  22 (2016)  3 - p. S98 , 2016
Link: https://doi.org/10.1016/..
 
1-15